• Gynecology Cancer Disease Site Group. Lukka H, Hirte H, Fyles A, Thomas G, Fung Kee Fung M, Johnston M. Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun [online update]. 27 p. (Practice guideline report; no. 4-5). [26 references]

• Women with cervical cancer for whom treatment with radiotherapy is being considered should be offered concurrent cisplatin with their course of radiotherapy. These women include:
  • Those with locally advanced cervical cancer
  • Those with bulky clinical stage IB (>4 cm) cervical cancer, who are treated with radiotherapy
  • Those with high-risk early-stage cervical cancer (node-positive or margin-positive), who will be treated with radiotherapy following hysterectomy
• There are no direct comparisons of different cisplatin regimens. Based on the review of the available toxicity data from the randomized controlled trials, the Disease Site Group felt that cisplatin should be given weekly (40 mg/m²).

None provided

The recommendations are supported by randomized controlled trials and meta-analyses.

• Gynecology Cancer Disease Site Group. Lukka H, Hirte H, Fyles A, Thomas G, Fung Kee Fung M, Johnston M. Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun [online update]. 27 p. (Practice guideline report; no. 4-5). [26 references]

Not applicable: The guideline was not adapted from another source.

2002 Aug 26 (revised 2004 Jun)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

The Practice Guidelines Initiative (PGI) is the main project of the Program in Evidence-based Care (PEBC), a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

Provincial Gynecology Disease Site Group

Members of the Gynecology Disease Site Group (DSG) disclosed potential conflict of interest information.

None available

This NGC summary was completed by ECRI on March 20, 2003. The information was verified by the guideline developer on May 8, 2003. This summary was updated by ECRI on January 23, 2004, and again on September 27, 2004. The updated information was verified by the guideline developer on October 20, 2004.